ERNA News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

ER

Mkt Cap

$2.4M

Volume

23.98K

Next Earnings

November 6th

Loading chart

ER

ERNAErnexa Therapeutics Inc. Common Stock

ERNA

Pay with—

Available Balance0.00

ER

Mkt Cap

$2.4M

Volume

23.98K

Next Earnings

November 6th

Chart Financials Earnings News About Insider Filings

Ernexa Therapeutics Announces Pricing of $10.5 Million Public OfferingErnexa Therapeutics (NASDAQ: ERNA) announced the pricing of a $10.5 million public offering of 21 million shares at $0.50 per share, along with warrants to purchase up to 21 million shares at $0.68 exercise price. The company plans to use proceeds to advance its cell therapy development programs, particularly ERNA-101 for ovarian cancer treatment. The offering is expected to close on February 10, 2026.Benzinga · Feb 6, 2026

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory DiseasesEterna Therapeutics to Present at ASGCT on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC LineGlobeNewswire Inc. · May 10, 2024

Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory BoardEterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory BoardGlobeNewswire Inc. · May 8, 2024

Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of DirectorsEterna Therapeutics (ERNA) Announces the Appointment of Peter Cicala, JD, to its Board of DirectorsGlobeNewswire Inc. · Feb 20, 2024

Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced that Eterna’s Board of Directors granted a non-qualified stock option to purchase 1,685,218 shares of Eterna’s common stock (the “Stock Option”) to its new President and Chief Executive Officer, Sanjeev Luther, effective January 1, 2024, the first date of his employment. The Stock Option was granted pursuant to the terms of Mr. Luther’s employment agreement and as a material inducement to his joining Eterna as President and Chief Executive Officer in accordance with Nasdaq Listing Rule 5635(c)(4).GlobeNewswire Inc. · Jan 3, 2024

Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer CAMBRIDGE, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, has appointed Sanjeev Luther as President and Chief Executive Officer and a member of the company's Board of Directors, effective January 1, 2024. Mr. Luther will replace Matt Angel, Ph.D., the current President and Chief Executive Officer.GlobeNewswire Inc. · Dec 20, 2023

Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant FinancingCAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the execution of a securities purchase agreement with accredited investors for the sale of approximately $9.2 million aggregate principal amount of senior convertible promissory notes and accompanying warrants to purchase an aggregate of 9,579,014 shares of common stock in a private placement transaction that was priced at-the-market under Nasdaq rules. The Company expects to hold an initial closing at which it expects to receive proceeds of approximately $7.8 million on December 15, 2023 and the remainder at a closing to occur no later than January 15, 2023.GlobeNewswire Inc. · Dec 14, 2023

Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of DirectorsCAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the appointment of James Bristol, Ph.D., to its Board of Directors.GlobeNewswire Inc. · Nov 1, 2023

Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell TherapeuticsmRNA cell engineering strategically targets genes to create novel and potentially superior product profiles for cell transplant therapy applicationsGlobeNewswire Inc. · Sep 6, 2023

Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of DirectorsCAMBRIDGE, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the appointment of Dorothy Clarke to its Board of Directors.GlobeNewswire Inc. · Sep 5, 2023

to start trading

ER

ERNAErnexa Therapeutics Inc. Common Stock

ERNA

Pay with—

Available Balance0.00

Your PositionYou don't own any ERNA yet.

Related Tickers

Earnings